Find Faculty
Paul J Kenny, PhD
img_Paul J Kenny
PROFESSOR & CHAIR | Neuroscience
DIRECTOR, DRUG DISCOVERY INSTITUTE
email
Research Topics
Addiction, Behavior, Brain, Drug Design and Discovery, Epigenetics, Gene Expressions, Molecular Biology, Neurobiology, Neuroscience, Obesity, Schizophrenia
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Genetics and Genomic Sciences [GGS]
The Kenny Laboratory is focused on understanding the neurobiological mechanisms of drug addiction, obesity and schizophrenia, with an emphasis on the role of nicotinic acetylcholine receptors (nAChRs) in these processes. They employ a multidisciplinary approach that includes complex behavioral paradigms, physiological analyses and molecular biological techniques. Current projects include the utilization of vector-based delivery systems to modify gene expression in the brains of rodents to identify novel signaling cascades that may play a role in addiction-like behaviors. Search PubMed for articles

BA, Trinity College Dublin

PhD, University of London

2020

Annual Alton Ochsner Award Relating Smoking and Disease

Ochsner Health

2018

Daniel H. Efron Research Award

American College of Neuropsychopharmacology (ACNP)

2015

Tom Connor Distinguished Investigator Award

Neuroscience Ireland

2012

Mathilde Solowey Lecture Award in the Neurosciences

Foundation for Advanced Education in the Sciences

2010

Jacob P. Waletzky Memorial Award

Society for Neuroscience

153
Publications

Selected Publications

Central and peripheral actions of nicotine that influence blood glucose homeostasis and the development of diabetes. Zuxin Chen, Xin an Liu, Paul J. Kenny. Pharmacological Research

Hedgehog-interacting protein acts in the habenula to regulate nicotine intake. Stephanie P.B. Caligiuri, William M. Howe, Lauren Wills, Alexander C.W. Smith, Ye Lei, Purva Bali, Mary P. Heyer, Janna K. Moen, Jessica L. Ables, Karim S. Elayouby, Maya Williams, Clementine Fillinger, Zainab Oketokoun, Vanessa E. Lehmann, Alexandra G. DiFeliceantonio, Paul M. Johnson, Kristin Beaumont, Robert P. Sebra, Ines Ibanez-Tallon, Paul J. Kenny. Proceedings of the National Academy of Sciences of the United States of America

Control of fear by discrete prefrontal GABAergic populations encoding valence-specific information. Kirstie A. Cummings, Sabina Bayshtok, Tri N. Dong, Paul J. Kenny, Roger L. Clem. Neuron

View All Publications

FBI Cyber Series - Nicotine Addiction: Unexpected Cells, Circuits, and Sicknesses by Paul Kenny, PhD
Paul Kenny, PhD, Director, Drug Discovery Institute

Hess CSM Building Floor 9 Room 116

1470 Madison Ave

New York, NY 10029

Hess CSM Building Floor 9th Floor Room Room 116

1470 Madison Ave

New York, NY 10029

212-824-8968

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Kenny during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

  • AstraZeneca
  • EpiVario

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Eolas Therapeutics, Inc.

Royalty Payments:

  • Eolas Therapeutics, Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.